Better Therapeutics, Inc. (BTTX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | - | - | 8000.00 | 18 Thousand |
| Cost of Revenue | 2.72 Million | 1.61 Million | 682 Thousand | 898 Thousand |
| Gross Profit | -2.72 Million | -1.61 Million | -674 Thousand | -880 Thousand |
| Operating Expenses | 38.26 Million | 30.56 Million | 5.64 Million | 4.89 Million |
| Selling, General and Administrative Expenses | 21.82 Million | 11.12 Million | 2.67 Million | 2.6 Million |
| Research and Development Expenses | 16.44 Million | 19.43 Million | 2.97 Million | 2.29 Million |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 38.26 Million | 30.56 Million | 6.33 Million | 5.79 Million |
| Operating Income | -38.26 Million | -30.56 Million | -6.32 Million | -5.77 Million |
| Interest Expense | 1.49 Million | 185 Thousand | 100 Thousand | 11 Thousand |
| Income Tax Expense | 7000.00 | -153 Thousand | 153 Thousand | 11 Thousand |
| Earnings before Tax | -39.75 Million | -40.48 Million | -6.23 Million | -5.78 Million |
| Net Income | -39.76 Million | -40.33 Million | -6.38 Million | -5.79 Million |
| Earnings Per Share Basic | -1.69 | -1.71 | -0.85 | -0.25 |
| Earnings Per Share Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Average Shares Outstanding | 23.55 Million | 23.6 Million | 7.55 Million | 23.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 23.55 Million | 23.6 Million | 7.55 Million | 23.59 Million |
| Gross Margin | - | - | -84.25 | -48.89 |
| EBIT Margin | - | - | -781.00 | -316.72 |
| Profit Margin | - | - | -798.38 | -321.94 |
| EBITDA | -38.26 Million | -30.56 Million | -6.24 Million | -5.7 Million |
| Earnings Before Tax Margin | - | - | -790.38 | -320.72 |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 841 Thousand | 797 Thousand | 755 Thousand | 2.72 Million | 721 Thousand | - |
| Gross Profit | -841 Thousand | -797 Thousand | -755 Thousand | -2.72 Million | -721 Thousand | - |
| Operating Expenses | 5.34 Million | 7.02 Million | 8.92 Million | 38.26 Million | 8.32 Million | 10.99 Million |
| Selling, General and Administrative Expenses | 3.5 Million | 4.78 Million | 5.53 Million | - | 5.27 Million | 5.51 Million |
| Research and Development Expenses | 1.83 Million | 2.24 Million | 3.38 Million | - | 3.04 Million | 5.47 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 5.34 Million | 7.02 Million | 8.92 Million | 38.26 Million | 8.32 Million | 10.99 Million |
| Operating Income | -5.34 Million | -7.02 Million | -8.92 Million | -38.26 Million | -8.32 Million | -10.99 Million |
| Interest Expense | -518 Thousand | 563 Thousand | 431 Thousand | 1.49 Million | 439 Thousand | 406 Thousand |
| Income Tax Expense | 3000.00 | 1000.00 | 1000.00 | 7000.00 | 4000.00 | 3000.00 |
| Earnings before Tax | -5.85 Million | -7.58 Million | -9.35 Million | -39.75 Million | -8.76 Million | -11.4 Million |
| Net Income | -5.86 Million | -7.58 Million | -9.35 Million | -39.76 Million | -8.76 Million | -11.4 Million |
| Earnings Per Share Basic | -0.15 | -0.24 | -0.39 | - | -0.37 | -0.48 |
| Earnings Per Share Diluted | -0.15 | -0.24 | -0.39 | - | -0.37 | -0.48 |
| Weighted Average Shares Outstanding | 38.49 Million | 31.21 Million | 23.82 Million | 23.55 Million | 23.74 Million | 23.69 Million |
| Weighted Average Shares Outstanding (Diluted) | 38.49 Million | 31.21 Million | 23.82 Million | 23.55 Million | 23.74 Million | 23.69 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -5.34 Million | -6.22 Million | -8.92 Million | - | -8.32 Million | -10.3 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
9022
BLHEF
VGO
2388
AGHOL
4980